52 related articles for article (PubMed ID: 38572842)
1. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
2. Severe adverse drug reactions.
Teo YX; Walsh SA
Clin Med (Lond); 2016 Feb; 16(1):79-83. PubMed ID: 26833523
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Allergol Select; 2017; 1(1):96-108. PubMed ID: 30402608
[TBL] [Abstract][Full Text] [Related]
4. Antiepileptic Medication-induced Severe Cutaneous Adverse Reactions in Hospitalized Children: A Retrospective Study.
Abtahi-Naeini B; Makhmali R; Amini N; Reza Maracy M; Nouri N; Momen T
Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):139-148. PubMed ID: 38822509
[TBL] [Abstract][Full Text] [Related]
5. [Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1790-1803. PubMed ID: 38782747
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases.
Bray ER; Lin RR; Li JN; Elgart GW; Elman SA; Maderal AD
Arch Dermatol Res; 2024 May; 316(6):233. PubMed ID: 38795205
[TBL] [Abstract][Full Text] [Related]
7. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK; Neulinger MM; Stadler PC; Aoki R; French LE
J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
[TBL] [Abstract][Full Text] [Related]
9. Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
J Cutan Med Surg; 2024; 28(1):51-58. PubMed ID: 38189282
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
12. Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications.
Bermeo-Ovalle A
Epilepsy Curr; 2019; 19(2):96-98. PubMed ID: 30955419
[TBL] [Abstract][Full Text] [Related]
13. An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions.
Hauben M; Hung E; Hsieh WY
Ther Adv Drug Saf; 2017 Jan; 8(1):4-16. PubMed ID: 28203363
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
